AU4645293A - The met proto-oncogene and a method for predicting breast cancer progression - Google Patents

The met proto-oncogene and a method for predicting breast cancer progression

Info

Publication number
AU4645293A
AU4645293A AU46452/93A AU4645293A AU4645293A AU 4645293 A AU4645293 A AU 4645293A AU 46452/93 A AU46452/93 A AU 46452/93A AU 4645293 A AU4645293 A AU 4645293A AU 4645293 A AU4645293 A AU 4645293A
Authority
AU
Australia
Prior art keywords
oncogene
breast cancer
cancer progression
met proto
predicting breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46452/93A
Inventor
Donna Faletto
Iafa Keydar
James H Resau
Ilan Tsarfaty
George F Vande Woude
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/903,588 external-priority patent/US6673559B1/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU4645293A publication Critical patent/AU4645293A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
AU46452/93A 1992-06-26 1993-06-25 The met proto-oncogene and a method for predicting breast cancer progression Abandoned AU4645293A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US903588 1992-06-26
US07/903,588 US6673559B1 (en) 1989-12-27 1992-06-26 Met proto-oncogene and a method for predicting breast cancer progression
PCT/US1993/005952 WO1994000764A1 (en) 1992-06-26 1993-06-25 The met proto-oncogene and a method for predicting breast cancer progression

Publications (1)

Publication Number Publication Date
AU4645293A true AU4645293A (en) 1994-01-24

Family

ID=25417739

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46452/93A Abandoned AU4645293A (en) 1992-06-26 1993-06-25 The met proto-oncogene and a method for predicting breast cancer progression

Country Status (2)

Country Link
AU (1) AU4645293A (en)
WO (1) WO1994000764A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
CN1172502A (en) * 1994-08-12 1998-02-04 亿万遗传股份有限公司 In vivo mutations and polymorphisms in 17 q -linked breast and ovarian cancer susceptibility gene
EP0699754B2 (en) * 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412116B1 (en) * 1988-04-18 1995-11-29 Oncogene Science, Inc. Detection of neu gene expression and products
EP0507868A4 (en) * 1989-12-27 1992-11-04 Us Commerce Diagnostic probe for detecting human stomach cancer

Also Published As

Publication number Publication date
WO1994000764A1 (en) 1994-01-06

Similar Documents

Publication Publication Date Title
AU2621092A (en) A ventilation method and means for the same
IL104273A0 (en) Double faced cutting insert
AU5543494A (en) Method and kit for cancer diagnosis
AU4645293A (en) The met proto-oncogene and a method for predicting breast cancer progression
AU1480497A (en) Cancer treatment
GB9509572D0 (en) Cancer therapy
AU3385693A (en) Determination method
AU7166896A (en) Cancer treatment
AU4309696A (en) Compacts
AU3398793A (en) Anti-tumor method and anti-tumor agent
GB9308166D0 (en) Cancer therapy
EP0581283A3 (en) Die coater
AU5414094A (en) Antineoplastic heteronaphthoquinones
HU9201811D0 (en) Processing technique
GB9306962D0 (en) Partitioning
AU5165993A (en) Pp14-based therapy
AU4261793A (en) Wedge-welding method
GB9200089D0 (en) Potentiometers
AU3377193A (en) Sulphonylbenzyl-substituted imidazoles
AU1493195A (en) Partitioning
AUPM458594A0 (en) Partitioning
GB9520556D0 (en) Digitiser tape
TW317202U (en) Die coater
GB9218860D0 (en) Steps
GB2302080B (en) Gantry